Drugs /

decitabine

Back to Drugs List

Overview

Generic Name(s):
decitabine
Trade Name(s):
Dacogen
NCI Definition [1]:
A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)

Clinical Trials

View Clinical Trials for decitabine

Decitabine has been investigated in 85 clinical trials, of which 61 are open and 24 are closed. Of the trials investigating decitabine, 2 are early phase 1 (2 open), 23 are phase 1 (18 open), 23 are phase 1/phase 2 (16 open), 25 are phase 2 (17 open), 2 are phase 2/phase 3 (1 open), 9 are phase 3 (7 open), and 1 is no phase specified (0 open).

del(5)(q10), Complex karyotype, and Monosomy 7 are the most frequent biomarker inclusion criteria for decitabine clinical trials.

Acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are the most common diseases being investigated in decitabine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Decitabine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Decitabine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating decitabine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Dacogen, 127716, 2'-deoxy-5-azacytidine, decitabine (product), 5-azadeoxycytidine, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-1,3,5-triazin-2(1h)-one, decitabine (substance), 2353-33-5, 50733, 5-aza-2'deoxycytidine, 2'-deoxy-5-azacytidine, azadc compound, 5-azadeoxycytidine, deoxyazacytidine, decitabine for injection, 5-aza-2-deoxycytidine, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-one, 5aza, 5-deoxyazacytidine, azadc, deoxyazacytidine, 5-aza-dcyd, 5-aza-2-deoxycytidine, decitabine, 5-aza-2'-deoxycytidine, dezocitidine, decitabine [chemical/ingredient], 5 aza 2 desoxycytidine, dac, 5 azadeoxycytidine, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-1,3,5-triazin-2(1h)-one, decitabine, 5-aza-2'-deoxycytidine, dezocitidine
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C981
SNOMED ID [1]:
F-620E7

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.